IBTA vs DSGX vs CDLX vs PERI vs ACMR

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -16. 2% for Cardlytics, Inc. (CDLX). The Descartes Systems Group Inc. (DSGX) offers the better valuation at 38. 4x trailing P/E (39. 3x forward), making it the more compelling value choice. Analysts rate Ibotta, Inc. (IBTA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Descartes Systems Group Inc.

(DSGX) is the cheapest at 38. 4x versus Ibotta, Inc. at 305. 9x. On forward P/E, Perion Network Ltd. is actually cheaper at 9. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ACM Research, Inc. wins at 0. 87x versus The Descartes Systems Group Inc. 's 1. 53x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +133. 4%, compared to -99. 2% for Cardlytics, Inc. (CDLX). Over 10 years, the gap is even starker: ACMR returned +31. 0% versus CDLX's -95. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Descartes Systems Group Inc.

(DSGX) is the lower-risk stock at 0. 65β versus ACM Research, Inc. 's 3. 17β — meaning ACMR is approximately 386% more volatile than DSGX relative to the S&P 500. On balance sheet safety, The Descartes Systems Group Inc. (DSGX) carries a lower debt/equity ratio of 1% versus 16% for ACM Research, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -16. 2% for Cardlytics, Inc. (CDLX). On earnings-per-share growth, the picture is similar: Cardlytics, Inc. grew EPS 50. 1% year-over-year, compared to -176. 0% for Perion Network Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Descartes Systems Group Inc.

(DSGX) is the more profitable company, earning 22. 5% net margin versus -44. 4% for Cardlytics, Inc. — meaning it keeps 22. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DSGX leads at 32. 3% versus -20. 2% for CDLX. At the gross margin level — before operating expenses — IBTA leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ACM Research, Inc. (ACMR) is the more undervalued stock at a PEG of 0. 87x versus The Descartes Systems Group Inc. 's 1. 53x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perion Network Ltd. (PERI) trades at 9. 1x forward P/E versus 39. 3x for The Descartes Systems Group Inc. — 30. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IBTA: 121. 7% to $81. 38.

In this comparison, ACMR (0.

2% yield) pays a dividend. IBTA, DSGX, CDLX, PERI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Descartes Systems Group Inc.

(DSGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +289. 5% 10Y return). Cardlytics, Inc. (CDLX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DSGX: +289. 5%, CDLX: -95. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IBTA (Technology) and DSGX (Technology) and CDLX (Communication Services) and PERI (Communication Services) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IBTA is a small-cap quality compounder stock; DSGX is a small-cap quality compounder stock; CDLX is a small-cap quality compounder stock; PERI is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.